Application of apolipoprotein E receptor mimetic peptide 6KApoEp in preparation of medicine for treating secondary brain injury after cerebral hemorrhage

An apolipoprotein and peptide-mimicking technology, applied in the field of cerebral hemorrhage treatment, can solve different problems, and achieve the effects of improving permeability, reducing inflammatory response, and reducing secondary brain injury

Active Publication Date: 2021-08-10
王丽琨
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Although the anti-inflammatory effect of 6KApoEp has been demonstrated in inflammatory models, the inflammatory response induced by LPS and thrombin after intracerebral hemorrhage may be different, and the results of studies at the cellular level and studies at the animal level may also be different ;Whether the modified 6KApoEp can effectively improve the permeability of the BBB after cerebral hemorrhage and effectively protect the secondary damage of spontaneous cerebral hemorrhage requires us to conduct further objective research and provide new treatment strategies and products for the destruction of the BBB after ICH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of apolipoprotein E receptor mimetic peptide 6KApoEp in preparation of medicine for treating secondary brain injury after cerebral hemorrhage
  • Application of apolipoprotein E receptor mimetic peptide 6KApoEp in preparation of medicine for treating secondary brain injury after cerebral hemorrhage
  • Application of apolipoprotein E receptor mimetic peptide 6KApoEp in preparation of medicine for treating secondary brain injury after cerebral hemorrhage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0057] The technical solution of the present invention is further described below, but the scope of protection is not limited to the description.

[0058] The apolipoprotein E receptor mimic peptide 6KApoEp is synthesized by adding 6 lysines (6K) to the 133-152 protein sequence of the low-density lipoprotein binding region in the ApoE gene. The amino acid sequence number of 6KApoEp is KKKKKLRVRLASHLRKLRKRLLRDA, where LRVRLASHLRKLRKRLL It is the amino acid sequence of No. 133-149 of apolipoprotein E (ApoE) in the brain.

[0059] A method for constructing an apolipoprotein E receptor mimic peptide 6KApoEp, comprising the following steps:

[0060] Step 1: Weigh the resin and put it into the peptide solid-phase synthesis tube, add dimethylformamide (DMF) to swell for more than half an hour;

[0061] Step 2: Remove dimethylformamide, and perform a 10min Fmoc (amino protecting group) deprotection reaction on a shaker with a protective solution; the protective solution is synthesize...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of apolipoprotein E receptor mimetic peptide 6KApoEp in preparation of a medicine for treating secondary brain injury after cerebral hemorrhage, and discloses a protein sequence of the apolipoprotein E receptor mimetic peptide 6KApoEp, a construction method of the protein sequence of the apolipoprotein E receptor mimetic peptide 6KApoEp and preparation of an application mixed solution; after the 6KApoEp is applied, the expression of CypA can be reduced; by inhibiting activation of a / MMP-9 pathway, cerebral edema and blood-brain barrier damage after cerebral hemorrhage and generation of proinflammatory factors are relieved; the brain water content is reduced, the BBB permeability is improved, the increase of blood-brain barrier related proteins such as claudin-5, occludin and ZO-1 is promoted, the inflammatory response after cerebral hemorrhage is regulated and controlled by inhibiting CypA / NF-KB / MMP-9, the water content of brain tissues is reduced, and the blood-brain barrier permeability is improved, so that the secondary brain injury after cerebral hemorrhage is relieved, and the neuroprotective effect on cerebral hemorrhage is achieved; the inflammatory response after cerebral hemorrhage is reduced, and the blood-brain barrier permeability is improved.

Description

technical field [0001] The invention relates to the application of an apolipoprotein E receptor mimic peptide 6KApoEp in the preparation of a drug for treating secondary brain injury after cerebral hemorrhage, and belongs to the technical field of cerebral hemorrhage treatment. Background technique [0002] Intracerebral hemorrhage (ICH) is the second common subtype of stroke, accounting for about 10% to 20% of all strokes, with an incidence of 10 to 30 people / 100,000 / year, and a 30-day mortality rate of 40%. Surviving ICH patients have severe neurological deficits, and only 20% of them can take care of themselves 6 months after the onset, and they still have a high risk of rebleeding and secondary stroke, which seriously threaten the life and health of patients. [0003] The pathophysiological mechanism after cerebral hemorrhage includes secondary brain damage in addition to the rapid accumulation of blood leading to the destruction of normal brain tissue anatomy and the me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P25/00C07K14/705C07K1/16C07K1/06C07K1/04
CPCA61K38/177A61P25/00C07K14/705
Inventor 王丽琨谭俊伍国锋任思颖
Owner 王丽琨
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products